Results of a Phase 1, Open-label, Single-dose, Parallel-group Study of Rimegepant 75 mg in Subjects with Hepatic Impairment (2126)

Determine the effect of hepatic impairment on the pharmacokinetics (PK) of a single 75 mg dose of rimegepant, a small molecule CGRP receptor antagonist with demonstrated efficacy and safety in migraine.